VectivBio Announces Results of Extraordinary General Meeting

Rhea-AI Summary

Wouter Joustra Joins VectivBio Board of Directors

On December 9, 2022, VectivBio Holding AG (Nasdaq: VECT) announced the election of Wouter Joustra to its Board of Directors during an Extraordinary General Meeting. Joustra brings extensive capital markets experience from his role at Forbion, a leading life sciences venture capital firm, where he focuses on late-stage life sciences investments. His expertise is expected to support VectivBio's growth strategy. The company is dedicated to developing treatments for severe rare conditions, including gastrointestinal diseases and inherited metabolic disorders.

Positive

• Wouter Joustra's election is expected to enhance VectivBio's strategic direction as the company enters a growth phase.
• Joustra brings substantial investment and capital markets experience from his background in life sciences.

Negative

• None.

-Wouter Joustra Elected to the Board of Directors

BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.

Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal origination, general portfolio management and divestment strategies, and focuses on Forbion´s Growth Opportunities Funds, which concentrates on investing in late stage life sciences companies. Previously, Mr. Joustra was a Senior Trader, as well as Executive Board member of the life sciences franchise at Kempen, a European boutique investment bank. In this role, Mr. Joustra managed Kempen’s trading portfolio, and he was involved in deal structuring and equity capital markets transactions, as well as larger block trades. Until Gyroscope Therapeutics’s acquisition by Novartis for up to $1.5 billion, Mr. Joustra served as a member of Gyroscope Therapeutics’s board of directors. Mr. Joustra is currently on the board of Forbion’s SPAC vehicle, Forbion European Acquisition Corp. (NASDAQ: FRBN), in addition to being a board observer at NewAmsterdam Pharma N.V. (NASDAQ: NAMS). Mr. Joustra holds an M.Sc. in Business Administration from the University of Groningen, and a B.Sc. in International Business and Management from this same university.

“We are pleased to add Wouter to the VectivBio Board of Directors. His deep experience in life-science capital markets will benefit VectivBio as we enter our next stage of growth,” said Tom Woiwode, VectivBio Board Chairman.

About VectivBio

VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Lead product candidate apraglutide is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD).

VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs). CoMET leverages innovative chemistry, based on a proprietary stabilized pantetheine backbone, to restore fundamental cellular metabolism in pediatric populations with IMDs characterized by a deficit of energy metabolism caused by the depletion of functional Coenzyme A (“CoA”). Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.

Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.

Contact:

Patrick Malloy
SVP, Investor Relations and Strategic Communications
VectivBio
Patrick.malloy@vectivbio.com

FAQ

Who is Wouter Joustra and why was he elected to VectivBio's Board of Directors?

Wouter Joustra is a General Partner at Forbion, a European life sciences venture capital firm, and was elected to VectivBio's Board on December 9, 2022, to enhance the company's growth strategy.

What is VectivBio focusing on with its product candidate apraglutide?

VectivBio's apraglutide is a long-acting synthetic GLP-2 analog aimed at treating rare gastrointestinal diseases like short bowel syndrome and Acute Graft-Versus-Host Disease.

What is VectivBio's CoMET platform?

CoMET is a modular platform developed by VectivBio to target previously undruggable inherited metabolic diseases, initially evaluating candidates for conditions like methylmalonic acidemia.

How does Wouter Joustra's experience benefit VectivBio?

Joustra's extensive experience in life sciences capital markets is expected to provide valuable insights and guidance as VectivBio seeks to expand its portfolio and market presence.